Founded in May, 1978, Farmindustria – the association of pharmaceutical companies and member of Confindustria – counts today about 200 national and foreign-owned member companies operating in Italy. Farmindustria, which is a member of the European (EFPIA) and International federations (IFPMA), pursues the achievement of a stable legislative framework and the outlining of policies by which the key role of pharmaceutical industry in enhancing the knowledge-based economy can get the right recognition, which may contribute to consolidating industrial presence on the territory and investments in research and manufacturing.
Contact
Largo del Nazareno, 3/8 – 00187 Roma
Phone: + 39 06 675801
Fax: + 39 06 6786494
email: farmindustria@farmindustria.it
Web: farmindustria.it
Massimo Scaccabarozzi, President of Farmindustria, discusses Italy’s response to the pandemic and the association’s key priorities, which include maintaining Italy’s position as a European leader in terms of production. Italy…
Massimo Scaccabarozzi, President of Farmindustria, talks about the potential of the pharmaceutical industry in Italy, the changes which need implementing to realize that potential and his vision for the industry’s…
As the CEO of Farmindustria since 1998, what would you say has been your recipe for the impressive success that the company has experienced, considering that Farmindustria represents 35% of…
Despite Italy being one of the most important pharmaceutical markets not only in Europe but also in the World, the industry remained quite stable for the last two years and…
A roundup of some of the biggest stories from Italian pharma and healthcare, including Italfarmaco’s FDA approval for its DMD treatment; Alfasigma’s acquisition of Galapagos’s Jyseleca, the antibiotics deal between…
The grants and loans allocated by the European Union’s Recovery and Resilience Facility (RRF), a large part of which have been assigned to healthcare, set out to mitigate the economic…
After former CEO Pierluigi Antonelli abruptly announced his departure last month, the Italian mid-cap has signed on former Gilead leader, Jacopo Andreose, as its new chief executive. [I am]…
Angelini Pharma CEO Pierluigi Antonelli has announced that he is leaving his position with immediate effect, posing the question of what comes next for the leading Italian mid-cap. Antonelli,…
The electoral victory of the centre-right coalition in Italy should see far-right firebrand Giorgia Meloni replace former European Central Bank President Mario Draghi as Prime Minister at the end of…
Digitalisation has become a buzz word in in the global life sciences sector. In Italy, digital transformation has taken on special significance as one of the principal goals encompassed in…
The Italian system requires drug companies to go through approvals at a national level with the Italian Medicines Agency (AIFA), only to then confront the country’s 21 regional authorities who…
Historically, SIFI has been a modest local player focused on ophthalmic products, but in recent years the company has set some ambitious goals for itself—becoming a leading force in European…
Seasoned executive Pierluigi Antonelli went from a career in big pharma to Angelini Pharma, a midsized Italian company that has been undergoing major transformation. He shares the motivation behind the…
Collectively representing almost 400 companies operating in Italy, Farmindustria, Egualia (formerly Assogenerici) and Assobiotec respectively promote the interests of innovative pharmaceutical companies—both foreign and Italian-owned— the generics, biosimilars and value-added…
As the European Union’s largest beneficiary of the Next Generation EU (NGEU) package, aimed at boosting the EU’s economy following the COVID-19 pandemic, Italy will receive some EUR 235 billion…
While Italy’s biotech landscape is generally held to be somewhat immature in comparison to more established markets such as Germany, France or the UK, that does not imply a deficit…
See our Cookie Privacy Policy Here
